

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

- 1-23. (canceled).
24. (previously presented) 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester.
25. (withdrawn) 15-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester.
26. (withdrawn) 13, 14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester.
27. (withdrawn) 15-(R)-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester.
28. (withdrawn) A compound selected from: 16-phenyl-17,18,19,20-tetranor-PGF_{2α}-isopropylester, 17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester, 16-phenoxy-17,18,19,20-tetranor-PGF_{2α}-isopropylester, 17-phenyl-18,19,20-trinor-PGE₂-isopropylester, 16-[4-(methoxy)-phenyl]-17,18,19,20-tetranor-PGF_{2α}-isopropylester, 18-phenyl-19,20-dinor-PGF_{2α}-isopropylester, and 19-phenyl-20-PGF_{2α}-isopropylester.
29. (previously presented) A therapeutic composition for the treatment of ocular hypertension or glaucoma in humans containing 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester in an amount sufficient to reduce intraocular pressure and an ophthalmologic compatible vehicle.
30. (withdrawn) A method of treating ocular hypertension or glaucoma in humans comprising topical administration of a therapeutically effective dose of the therapeutic composition of claim 29.
31. (withdrawn) A therapeutic composition for the treatment of ocular hypertension or glaucoma in humans containing 15-dehydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester in an amount sufficient to reduce intraocular pressure and an ophthalmologic compatible vehicle.

32. (withdrawn) A method of treating ocular hypertension or glaucoma in humans comprising topical administration of a therapeutically effective dose of the therapeutic composition of claim 31.

33. (withdrawn) A therapeutic composition for the treatment of ocular hypertension or glaucoma in humans containing 13,14-dihydro-17-phenyl-18,19,20-trinor-PGA₂-isopropylester in an amount sufficient to reduce intraocular pressure and an ophthalmologic compatible vehicle.

34. (withdrawn) A method of treating ocular hypertension or glaucoma in humans comprising topical administration of a therapeutically effective dose of the therapeutic composition of claim 33.

35. (withdrawn) A therapeutic composition for the treatment of ocular hypertension or glaucoma in humans containing 15-(R)-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropylester in an amount sufficient to reduce intraocular pressure and an ophthalmologic compatible vehicle.

36. (withdrawn) A method of treating ocular hypertension or glaucoma in humans comprising topical administration of a therapeutically effective dose of the therapeutic composition of claim 35.

37. (withdrawn) A therapeutic composition for the treatment of ocular hypertension or glaucoma in humans containing a compound of claim 28 in an amount sufficient to reduce intraocular pressure and an ophthalmologic compatible vehicle.

38. (withdrawn) A method of treating ocular hypertension or glaucoma in humans comprising topical administration of a therapeutically effective dose of the therapeutic composition of claim 37.